BeOne Medicines (NASDAQ:ONC) Given New $435.00 Price Target at Wells Fargo & Company

Key Points

• Wells Fargo raised its price target on BeOne Medicines to $435 from $400 and maintained an “overweight” rating, implying 6.83% upside from the prior close. Analysts’ consensus rating is “Moderate Buy,” with an average target of $426.59.
• BeOne’s third-quarter results beat expectations: earnings were $3.64 per share versus $2.34 expected, and revenue was $1.89 billion versus $1.76 billion. The company also raised its 2026 revenue guidance.
• The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma, potentially speeding a decision on expanding the treatment’s use.

BeOne Medicines (NASDAQ:ONC - Get Free Report) had its target price upped by investment analysts at Wells Fargo & Company from $400.00 to $435.00 in a report released on Friday, Benzinga reports. The firm presently has an "overweight" rating on the stock. Wells Fargo & Company's price objective would indicate a potential upside of 6.83% from the company's previous close.

ONC has been the topic of several other research reports. Citigroup reissued an "outperform" rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Truist Financial upped their price target on BeOne Medicines from $418.00 to $420.00 and gave the stock a "buy" rating in a research note on Wednesday, October 7th. Zacks Research lowered shares of BeOne Medicines from a "strong-buy" rating to a "hold" rating in a report on Monday, October 5th. JPMorgan Chase & Co. lifted their price objective on shares of BeOne Medicines from $425.00 to $445.00 and gave the company an "overweight" rating in a research report on Thursday, October 1st. Finally, Royal Bank Of Canada boosted their target price on shares of BeOne Medicines from $450.00 to $459.00 and gave the stock an "outperform" rating in a report on Thursday, October 8th. Sixteen analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, BeOne Medicines presently has a consensus rating of "Moderate Buy" and an average target price of $426.59.

BeOne Medicines Price Performance

BeOne Medicines stock traded up $19.94 during mid-day trading on Friday, hitting $407.19. The stock had a trading volume of 189,636 shares, compared to its average volume of 316,714. BeOne Medicines has a one year low of $253.95 and a one year high of $406.00. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $44.70 billion, a P/E ratio of 71.54 and a beta of 0.63. The firm's 50 day moving average is $362.80 and its 200 day moving average is $325.98.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $3.64 EPS for the quarter, beating the consensus estimate of $2.34 by $1.30. The business had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.76 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. On average, sell-side analysts forecast that BeOne Medicines will post 8.99 earnings per share for the current fiscal year.

Insider Transactions at BeOne Medicines

In other news, SVP Chan Lee sold 2,666 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $360.00, for a total transaction of $959,760.00. Following the completion of the transaction, the senior vice president directly owned 812 shares in the company, valued at approximately $292,320. This represents a 76.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 280 shares of the firm's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total transaction of $106,400.00. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 376,373 shares of company stock worth $134,848,154. 6.19% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors have recently bought and sold shares of the business. Bank of America Corp DE lifted its stake in BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company's stock worth $120,354,000 after purchasing an additional 26,441 shares during the last quarter. Baird Financial Group Inc. raised its holdings in shares of BeOne Medicines by 5.5% in the second quarter. Baird Financial Group Inc. now owns 368,978 shares of the company's stock worth $105,148,000 after buying an additional 19,327 shares during the period. Candriam S.C.A. raised its holdings in shares of BeOne Medicines by 31.7% in the first quarter. Candriam S.C.A. now owns 259,731 shares of the company's stock worth $77,132,000 after buying an additional 62,470 shares during the period. First Trust Advisors LP lifted its stake in shares of BeOne Medicines by 91.9% during the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company's stock worth $71,696,000 after acquiring an additional 115,601 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in shares of BeOne Medicines by 102.1% during the 1st quarter. Jennison Associates LLC now owns 154,465 shares of the company's stock worth $45,871,000 after acquiring an additional 78,027 shares during the last quarter. Institutional investors own 48.55% of the company's stock.

Key Headlines Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported third-quarter EPS of $3.64, topping the $2.34 consensus estimate, while revenue of $1.89 billion exceeded expectations of $1.76 billion. The company also raised its 2026 revenue guidance, adding to the positive outlook. BeOne Medicines Q3 Adjusted Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. The review could bring a decision on the potential label expansion sooner, creating an opportunity to broaden the treatment’s use if approved. FDA Priority Review for BRUKINSA Combination

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.